Why Gilead Sciences Is Poised to Keep Poppin'

Brian Pacampara, The Motley Fool
Updated

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant has earned a respected four-star ranking.

With that in mind, let's take a closer look at Gilead, and see what CAPS investors are saying about the stock right now.

Gileadfacts

Headquarters (founded)

Foster City, Calif. (1987)

Market Cap

$85.1 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$10.0 billion

Management

Chairman/CEO John Martin

President/COO John Milligan

36.5%

Cash/Debt

$1.9 billion / $8.0 billion

Competitors

Bristol-Myers Squibb

GlaxoSmithKline

Pfizer


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,253 members who have rated Gilead believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, TMFTailwind, succinctly summed up the Gilead bull case for our community:

Very profitable company, and I expect [Gilead's] streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Gilead may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

The article Why Gilead Sciences Is Poised to Keep Poppin' originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement